Investing with a Dream
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks ockid, I will make my position official on the 31st.
Wasn't a great year, amazing they still have a long long shot for playoffs. You are correct though, I am more excited about my long term stock choices than the Steelers right now.
Thanks Crazy, I will be taking the ACYD plunge on the 31st. This looks to good to pass up. I am used to waiting for profits so I'll buy ACYD and lock my shares up with my other long term stocks.
martin, with the Q&A posted on ScripsAmerica website along with the additional comments/perspective provided by Bsav, there is no reason why SCRC shouldn't be a stock in everyone's portfolio. These penny prices are not going to last much longer. 97% of the posters on this board have nothing but great things to say about SCRC. Q1 2014 will be the launch and the next five quarters will be explosive.
cwell, I am very comfortable with the projections posted. I too have the patience to endure. I sold Glaxo and Amgen way to soon. I've learned from that experience. SCRC is on the verge of greatness and I look forward to the day we all get together and celebrate this HUGE SUCCESS. GO SCRC 2014!!![/b]
As I read through the Q&A for a second time, one response caught my eye. Below is the response to the question relating to the company's ultimate goal for its drug supply chain business model.
Management believes this opportunity alone will generate sufficient revenues to enable ScripsAmerica to be uplifted to a major exchange by 2015.
Talk about confidence in a business plan/model. SCRC in 2014 will be an incredible investment opportunity. SCRC in 2015, what else can be said? ScripsAmerica is a company on the move.
Bsav, this Q&A document is AWESOME. I have invested in several penny stocks in the last two years and I have never seen anything so comprehensive and transparent prepared by a company CEO before. Bob Schneiderman has gone out of his way to provide all of us investors and new investors with answers to every possible question one could have. If anyone ever questioned the direction of ScripsAmerica, this Q&A needs to be read. With the current investor excitement brewing for an exciting and explosive 2014 this Q&A document is very much appreciated and perfectly timed. SCRC 2014!!!
Yes HaasCat, incredible volume. SCRC will be enormous in 2014. Everything is pointing North. Go SCRC 2014!!!
RockyW, the list of well respected posters is massive and in my eyes you have just joined that list. Your projections are very realistic. Bsav has been a powerful influence and carries a lot of clout. Enjoy the ride.
Thanks Tut.
You are so right kaleb. The RapiMeds technology is incredible. With the Pediatric RapiMeds mothers are going to be amazed with how fast it dissolves but most importantly how quickly the acetaminophen is absorbed into the system. Healthier kids without the problem of swallowing a pill or spitting out a pill/tablet. Yes there are other melt-away products available but none will come close to matching Pediatric RapiMeds. We have the right product, the right company, and the right CEO in Bob Schneiderman running the entire operation. 2014 WILL BE an exciting year for investors.
Great info Bsav, thanks. SCRC is a solid company with a solid group of investors who know the potential of SCRC in 2014. SCRC in 2014 will be AWESOME!!!
Thanks Tut. The facts are the facts. Go SCRC in 2014!!!
Scroll down and you will see RapiMeds and all the other approved products containing acetaminophen.
Rx and OTC medications containing acetaminophen
The maximum total daily dose of acetaminophen administered by any route should not be exceeded. To minimize the potential risk of overdose, HCPs should discuss with their patients the
use and amounts of acetaminophen contained in both prescription and OTC medications.
This list is designed to serve as a guide and is not meant to be a comprehensive directory of all available acetaminophen-containing products. It is important to
carefully review any product’s list of ingredients to determine whether and how much acetaminophen is contained within. Please refer to individual product labels for
specific dosing guidelines.
Acetaminophen and Oxycodone Combinations
Endocet® Percocet® Roxicet® Tylox®
Acetaminophen and Hydrocodone Combinations
Lorcet® Norco® Vicodin ES® Xodol®
Lortab® Vicodin® Vicodin HP® Zydone®
Acetaminophen and Propoxyphene Combinations
Darvocet® Darvocet-N®
Acetaminophen, Chlorpheniramine, Phenylephrine,
and Phenyltoloxamine Combinations
Norel® SR
Acetaminophen, Butalbital, and Caffeine Combinations
Dolgic® Plus Esgic® Fioricet® Zebutal®
Acetaminophen, Dihydrocodeine, and Caffeine Combinations
TrezixTM
Acetaminophen and Codeine Combinations
Capital® w/codeine Fioricet® w/codeine Tylenol® w/codeine
Acetaminophen and Tramadol Combinations
Ultracet®
OFIRMEV® (acetaminophen) injection
Acetaminophen Single-Agent Products
Acephen® Suppositories
Cetafen® (various products under this brand name)
Children’s Silapap® Elixir
Children’s Tylenol® (various products under this brand name)
Ed-APAP® Children’s Solution
ElixSure® Children’s Fever Reducer/Pain Reliever
FeverAll® Suppositories
Genapap® (various products under this brand name)
Jr. Tylenol® Meltaways
Mapap® (various products under this brand name)
Nortemp® Children’s Suspension
Q-Pap® (various products under this brand name)
RapiMed®
Silapap® (various products under this brand name)
Tylenol® 8 Hour
Tylenol® Arthritis Pain
Tylenol® Extra Strength (various products under this brand name)
Tylenol® Infants’ Drops
Tylenol® Regular Strength
Valorin® (various products under this brand name)
Acetaminophen Combination Products
Alka-Seltzer® (various products under this brand name)
Anacin® Advanced Headache Formula
Benadryl® (various products under this brand name)
Co-APAP® Cough Formula M Multi-Symptom
Comtrex® (various products under this brand name)
Contac® (various products under this brand name)
Coricidin® (various products under this brand name)
DayQuil® (various products under this brand name)
Dimetapp® (various products under this brand name)
Dristan® Cold
Excedrin® Back and Body
Excedrin® Extra Strength (various products under this brand name)
Excedrin® Menstrual Complete
Excedrin® Migraine
Excedrin® Tension Headache
Goody’s® Headache Powders (various products under this brand name)
Mapap® (various products under this brand name)
Midol® (various products under this brand name)
NyQuil® (various products under this brand name)
Robitussin® (various products under this brand name)
Sudafed® (various products under this brand name)
Theraflu® (various products under this brand name)
Triaminic® (various products under this brand name)
Tylenol® Cold (various products under this brand name)
Vanquish® Caplets
Vicks® Formula 44® (various products under this brand name)
This list is provided as an educational service by Cadence Pharmaceuticals, Inc.
All brand names used in this communication are trademarks of their respective owners.
©2013 Cadence Pharmaceuticals, Inc. OFV12630613
For additional information regarding OFIRMEV,
please see the accompanying full Prescribing Information.
Revised 07/2013
OTC products containing acetaminophen (examples)
Prescription intravenous product containing acetaminophen
Prescription oral products containing acetaminophen (examples)
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed
to use OFIRMEV® safely and effectively. See full prescribing
information for OFIRMEV.
OFIRMEV (acetaminophen) Injection
Initial U.S. Approval: 1951
INDICATIONS AND USAGE
OFIRMEV (acetaminophen) injection is indicated for the
• Management of mild to moderate pain (1)
• Management of moderate to severe pain with adjunctive
opioid analgesics (1)
• Reduction of fever (1)
DOSAGE AND ADMINISTRATION
• OFIRMEV may be given as a single or repeated dose. (2.1)
• OFIRMEV should be administered only as a 15-minute
intravenous infusion. (2.4)
Adults and Adolescents Weighing 50 kg and Over:
• 1000 mg every 6 hours or 650 mg every 4 hours to a
maximum of 4000 mg per day. Minimum dosing interval
of 4 hours. (2.2)
Adults and Adolescents Weighing Under 50 kg:
• 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours to a
maximum of 75 mg/kg per day. Minimum dosing interval
of 4 hours. (2.2)
Children:
• Children = 2 to 12 years old: 15 mg/kg every 6 hours or
12.5 mg/kg every 4 hours to a maximum of 75 mg/kg per
day. Minimum dosing interval of 4 hours. (2.3)
DOSAGE FORMS AND STRENGTHS
• Injection for intravenous infusion.
• Each 100 mL glass vial contains 1000 mg acetaminophen
(10 mg/mL). (3)
CONTRAINDICATIONS
Acetaminophen is contraindicated:
• In patients with known hypersensitivity to acetaminophen
or to any of the excipients in the IV formulation. (4)
• In patients with severe hepatic impairment or severe active
liver disease. (4)
WARNINGS AND PRECAUTIONS
• Administration of acetaminophen in doses higher than
recommended may result in hepatic injury, including the
risk of severe hepatotoxicity and death. (5.1)
• Do not exceed the maximum recommended daily dose of
acetaminophen. (5.1)
• Use caution when administering acetaminophen in patients
with the following conditions: hepatic impairment or
active hepatic disease, in cases of alcoholism, chronic
malnutrition, severe hypovolemia, or severe renal
impairment (creatinine clearance = 30 mL/min). (5.1)
• Discontinue OFIRMEV immediately if symptoms
associated with allergy or hypersensitivity occur. Do not
use in patients with acetaminophen allergy. (5.2)
ADVERSE REACTIONS
The most common adverse reactions in patients treated with
OFIRMEV were nausea, vomiting, headache, and insomnia
in adult patients and nausea, vomiting, constipation, pruritus,
agitation, and atelectasis in pediatric patients. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact
Cadence Pharmaceuticals Inc. at 1-877-647-2239 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
• Substances that induce or regulate hepatic cytochrome
enzyme CYP2E1 may alter the metabolism of
acetaminophen and increase its hepatotoxic potential. (7.1)
• Chronic oral acetaminophen use at a dose of 4000 mg/day has
been shown to cause an increase in international normalized
ratio (INR) in some patients who have been stabilized on
sodium warfarin as an anticoagulant. (7.2)
USE IN SPECIFIC POPULATIONS
• Pregnancy: Category C. There are no studies of intravenous
acetaminophen in pregnant women. Use only if clearly
needed. (8.1)
• Nursing Mothers: Caution should be exercised when
administered to a nursing woman. (8.3)
• Pediatric Use: The effectiveness of OFIRMEV for the
treatment of acute pain and fever has not been studied
in pediatric patients less than 2 years of age. The safety
and effectiveness of OFIRMEV in pediatric patients older
than 2 years is supported by evidence from adequate and
well controlled studies in adults with additional safety and
pharmacokinetic data for this age group. (8.4)
• Geriatric Use: No overall differences in safety or
effectiveness were observed between geriatric and younger
subjects. (8.5)
• Hepatic Impairment: OFIRMEV is contraindicated in
patients with severe hepatic impairment or severe active
liver disease and should be used with caution in patients
with hepatic impairment or active liver disease. (4, 5.1, 8.6)
• Renal Impairment: In cases of severe renal impairment,
longer dosing intervals and a reduced total daily dose of
acetaminophen may be warranted. (5.1, 8.7)
Revised: 11/2010
FULL PRESCRIBING INFORMATION: CONTENTS*
1. INDICATIONS AND USAGE
2. DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
2.2 Recommended Dosage: Adults and Adolescents
2.3 Recommended Dosage: Children
2.4 Instructions for Intravenous Administration
3. DOSAGE FORMS AND STRENGTHS
4. CONTRAINDICATIONS
5. WARNINGS AND PRECAUTIONS
5.1 Hepatic Injury
5.2 Allergy and Hypersensitivity
6. ADVERSE REACTIONS
6.1 Clinical Trial Experience
7. DRUG INTERACTIONS
7.1 Effects of other Substances on Acetaminophen
7.2 Anticoagulants
8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Labor and Delivery
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Patients with Hepatic Impairment
8.7 Patients with Renal Impairment
10. OVERDOSAGE
11. DESCRIPTION
12. CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13. NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14. CLINICAL STUDIES
14.1 Adult Acute Pain
14.2 Adult Fever
14.3 Pediatric Acute Pain and Fever
16. HOW SUPPLIED/STORAGE AND HANDLING
*Sections or subsections omitted from the full prescribing information
are not listed.
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
OFIRMEV® (acetaminophen) injection is
indicated for
• the management of mild to moderate pain
• the management of moderate to severe pain
with adjunctive opioid analgesics
• the reduction of fever.
2 DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
OFIRMEV may be given as a single or
repeated dose for the treatment of acute pain
or fever. No dose adjustment is required when
converting between oral acetaminophen and
OFIRMEV dosing in adults and adolescents. The
maximum daily dose of acetaminophen is based
on all routes of administration (i.e. intravenous,
oral, and rectal) and all products containing
acetaminophen.
2.2 Recommended Dosage: Adults and
Adolescents
Adults and adolescents weighing 50 kg and
over: the recommended dosage of OFIRMEV is
1000 mg every 6 hours or 650 mg every 4 hours,
with a maximum single dose of OFIRMEV of
1000 mg, a minimum dosing interval of 4 hours,
and a maximum daily dose of acetaminophen of
4000 mg per day.
Adults and adolescents weighing under
50 kg: the recommended dosage of OFIRMEV is
15 mg/kg every 6 hours or 12.5 mg/kg every
4 hours, with a maximum single dose of
OFIRMEV of 15 mg/kg, a minimum dosing
interval of 4 hours, and a maximum daily dose of
acetaminophen of 75 mg/kg per day.
2.3 Recommended Dosage: Children
Children = 2 to 12 years of age: the
recommended dosage of OFIRMEV is 15 mg/kg
every 6 hours or 12.5 mg/kg every 4 hours,
with a maximum single dose of OFIRMEV of
15 mg/kg, a minimum dosing interval of 4 hours,
and a maximum daily dose of acetaminophen of
75 mg/kg per day.
2.4 Instructions for Intravenous Administration
For adult and adolescent patients weighing
= 50 kg requiring 1000 mg doses of OFIRMEV,
administer the dose by inserting a vented
intravenous set through the septum of the
100 mL vial. OFIRMEV may be administered
without further dilution. Examine the vial contents
before dose preparation or administering. DO
NOT USE if particulate matter or discoloration
is observed. Administer the contents of the vial
intravenously over 15-minutes. Use aseptic
technique when preparing OFIRMEV for
intravenous infusion. Do not add other medications
to the OFIRMEV vial or infusion device.
For doses less than 1000 mg, the
appropriate dose must be withdrawn from
the vial and placed into a separate container
prior to administration. Using aseptic technique,
withdraw the appropriate dose (650 mg or weightbased)
from an intact sealed OFIRMEV vial and
place the measured dose in a separate empty, sterile
container (e.g. glass bottle, plastic intravenous
container, or syringe) for intravenous infusion to
avoid the inadvertent delivery and administration
of the total volume of the commercially available
container. The entire 100 mL vial of OFIRMEV
is not intended for use in patients weighing less
than 50 kg. OFIRMEV is a single-use vial and the
unused portion must be discarded.
Place small volume pediatric doses up to
60 mL in volume in a syringe and administer over
15 minutes using a syringe pump.
Monitor the end of the infusion in order
to prevent the possibility of an air embolism,
especially in cases where the OFIRMEV infusion
is the primary infusion.
Once the vacuum seal of the glass vial has
been penetrated, or the contents transferred
to another container, administer the dose of
OFIRMEV within 6 hours.
Do not add other medications to
the OFIRMEV solution. Diazepam and
chlorpromazine hydrochloride are physically
incompatible with OFIRMEV, therefore do not
administer simultaneously.
3 DOSAGE FORMS AND STRENGTHS
OFIRMEV is a sterile, clear, colorless, non
pyrogenic, preservative free, isotonic formulation
of acetaminophen intended for intravenous
infusion. Each 100 mL glass vial contains
1000 mg acetaminophen (10 mg/mL).
4 CONTRAINDICATIONS
Acetaminophen is contraindicated:
• in patients with known hypersensitivity to
acetaminophen or to any of the excipients in
the intravenous formulation.
• in patients with severe hepatic impairment or
severe active liver disease [see WARNINGS
AND PRECAUTIONS (5.1)].
5 WARNINGS AND PRECAUTIONS
5.1 Hepatic Injury
Administration of acetaminophen in doses
higher than recommended may result in hepatic
injury, including the risk of severe hepatotoxicity
and death [see OVERDOSAGE (10)]. Do not
exceed the maximum recommended daily
dose of acetaminophen [see DOSAGE AND
ADMINISTRATION (2)].
Use caution when administering
acetaminophen in patients with the following
conditions: hepatic impairment or active hepatic
disease, alcoholism, chronic malnutrition, severe
hypovolemia (e.g., due to dehydration or blood
loss), or severe renal impairment (creatinine
clearance = 30 mL/min) [see USE IN SPECIFIC
POPULATIONS (8.6, 8.7)].
5.2 Allergy and Hypersensitivity
There have been post-marketing reports of
hypersensitivity and anaphylaxis associated with
the use of acetaminophen. Clinical signs included
swelling of the face, mouth, and throat, respiratory
distress, urticaria, rash, and pruritus. There were
infrequent reports of life-threatening anaphylaxis
requiring emergent medical attention. Discontinue
OFIRMEV immediately if symptoms associated
with allergy or hypersensitivity occur. Do not
use OFIRMEV in patients with acetaminophen
allergy.
6 ADVERSE REACTIONS
The following serious adverse reactions are
discussed elsewhere in the labeling:
• Hepatic Injury [see WARNINGS AND
PRECAUTIONS (5.1)]
• Allergy and Hypersensitivity [see WARNINGS
AND PRECAUTIONS (5.2)]
6.1 Clinical Trial Experience
Because clinical trials are conducted under
widely varying conditions, adverse reaction rates
observed cannot be directly compared to rates in
other clinical trials and may not refl ect the rates
observed in practice.
Adult Population
A total of 1020 adult patients have received
OFIRMEV in clinical trials, including 37.3%
(n=380) who received 5 or more doses, and 17.0%
(n=173) who received more than 10 doses. Most
patients were treated with OFIRMEV 1000 mg
every 6 hours. A total of 13.1% (n=134) received
OFIRMEV 650 mg every 4 hours.
All adverse reactions that occurred in adult
patients treated with either OFIRMEV or placebo
in repeated dose, placebo-controlled clinical trials
at an incidence = 3% and at a greater frequency
than placebo are listed in Table 2. The most
common adverse events in adult patients treated
with OFIRMEV (incidence = 5% and greater than
placebo) were nausea, vomiting, headache, and
insomnia.
* Pyrexia adverse reaction frequency data is included in
order to alert healthcare practitioners that the antipyretic
effects of OFIRMEV may mask fever.
Other Adverse Reactions Observed During
Clinical Studies of OFIRMEV in Adults
The following additional treatment-emergent
adverse reactions were reported by adult subjects
treated with OFIRMEV in all clinical trials
(n=1020) that occurred with an incidence of at
least 1% and at a frequency greater than placebo
(n=525).
Blood and lymphatic system disorders: anemia
General disorders and administration site
conditions: fatigue, infusion site pain, edema
peripheral
Investigations: aspartate aminotransferase
increased, breath sounds abnormal
Table 1: Dosing for Adults and Adolescents
Age group Dose given Dose given Maximum Maximum total
daily dose of
acetaminophen
(by any routes)
every 4 every 6 hours single dose
Adults and
adolescents
(13 years and
older) weighing
??????????????
Adults and
adolescents
(13 years and
older) weighing
??????????????
650 mg 1000 mg 1000 mg 4000 mg in
24 hours
12.5 mg/kg 15 mg/kg 15 mg/kg 75 mg/kg in
(up to 750 mg) 24 hours
(up to 3750 mg)
hours
Table 2. Treatment-Emergent Adverse Reactions Occurring
?? ??% in OFIRMEV and at a greater frequency than Placebo
in Placebo-Controlled, Repeated Dose Studies
System Organ Class – Preferred Term OFIRMEV
(N=402)
n (%)
Placebo
(N=??????)
n (%)
Gastrointestinal Disorders
Nausea
Vomiting
138 (34)
62 (15)
119 (31)
42 (11)
General Disorders and Administration
Site Conditions
Pyrexia* 22 (5) 52 (14)
Nervous System Disorders
Headache 39 (10) 33 (9)
Psychiatric Disorders
Insomnia 30 (7) 21 (5)
Metabolism and nutrition disorders: hypokalemia
Musculoskeletal and connective tissue disorders:
muscle spasms, trismus
Psychiatric disorders: anxiety
Respiratory, thoracic and mediastinal disorders:
dyspnea
Vascular disorders: hypertension, hypotension
Pediatric population
A total of 355 pediatric patients (47 neonates,
64 infants, 171 children, and 73 adolescents)
have received OFIRMEV in active-controlled
(n=250) and open-label clinical trials (n=225),
including 59.7% (n=212) who received 5 or
more doses and 43.1% (n=153) who received
more than 10 doses. Pediatric patients received
OFIRMEV doses up to 15 mg/kg on an every 4
hours, every 6 hours, or every 8 hours schedule.
The maximum exposure was 7.7, 6.4, 6.8, and
7.1 days in neonates, infants, children, and
adolescents, respectively.
The most common adverse events (incidence
= 5%) in pediatric patients treated with
OFIRMEV were nausea, vomiting, constipation,
pruritus, agitation, and atelectasis.
Other Adverse Reactions Observed During
Clinical Studies of OFIRMEV in Pediatrics
The following additional treatment-emergent
adverse reactions were reported by pediatric
subjects treated with OFIRMEV (n=355) that
occurred with an incidence of at least 1%.
Blood and lymphatic system disorders: anemia
Cardiac disorders: tachycardia
Gastrointestinal disorders: abdominal pain,
diarrhea
General disorders and administration site
conditions: injection site pain, edema peripheral,
pyrexia
Investigations: hepatic enzyme increase
Metabolism and nutrition disorders:
hypoalbuminemia, hypokalemia,
hypomagnesemia, hypophosphatemia,
hypervolemia
Musculoskeletal and connective tissue disorders:
muscle spasm, pain in extremity
Nervous system disorders: headache
Psychiatric disorders: insomnia
Renal and urinary disorders: oliguria
Respiratory, thoracic and mediastinal disorders:
pulmonary edema, hypoxia, pleural effusion,
stridor, wheezing
Skin and subcutaneous tissue disorders:
periorbital edema, rash
Vascular disorders: hypertension, hypotension
7 DRUG INTERACTIONS
7.1 Effects of other Substances on
Acetaminophen
Substances that induce or regulate hepatic
cytochrome enzyme CYP2E1 may alter the
metabolism of acetaminophen and increase its
hepatotoxic potential. The clinical consequences
of these effects have not been established. Effects
of ethanol are complex, because excessive alcohol
usage can induce hepatic cytochromes, but
ethanol also acts as a competitive inhibitor of the
metabolism of acetaminophen.
7.2 Anticoagulants
Chronic oral acetaminophen use at a dose of
4000 mg/day has been shown to cause an increase
102199_OFIRMEV.indd 1 6/8/11 5:25 PM
ScripsAmerica to secure distribution commitments for its RapiMed in China
PBR Staff Writer
Published 29 October 2013
ScripsAmerica has reported that its due diligence team will start formal distribution negotiations in November 2013 in preparation for the launch of its RapiMed children's pain reliever and fever reducer into the Chinese OTC market, valued at over $32bn.
In this regard, the company is planning to secure distribution commitments for its product across China, with its representatives conducting many meetings with hospitals, pharmacies, multi-level marketing companies and pharmaceutical sales networks.
ScripsAmerica CEO Bob Schneiderman said the company is confident that its upcoming ventures in China will produce strong sales revenue.
"ScripsAmerica believes RapiMed(R)'s ease of delivery and American-made quality assurance is the right product at the right time for the Chinese market," Schneiderman said.
The company will carry out pharmaceutical distribution meetings in the cities of Hong Kong, Chengdu, Yantai, Shenzhen and Beijing.
In addition, ScripsAmerica has already started to formally register RapiMed with the Chinese State Food and Drug Administration which will enable it to market and sell the product across the Chinese Market.
In a previous post I mentioned the SCRC investors bring with them a lot of clout. I know for a fact that within the SCRC investment family, we have over 125 years of pharmaceutical experience, I personally have over 35 years of pharma experience. I also know we have pharmacists and nurses who have invested seriously in SCRC. Not only do we see SCRC as a great investment opportunity, but we also see the value of Pediatric RapiMeds and the RapiMeds technology as an improved delivery method for medications. Also, I took the opportunity to step out and speak with other investors to see why they invested in SCRC. What I found was I ended up speaking a retired professor from a university in Tuscany and several prominent executives with prestigious companies across the U.S. Like I said, SCRC is not your typical penny stock. SCRC has attracted investors from all across the financial spectrum. Whether you are a small time investor with a few bucks and a dream or a big player in the stock market, SCRC is the place for you. Bob Schneiderman, SCRC CEO, has developed a well-diversified business model with untapped potential. Call Bob, yes, we have a CEO who even with his busy schedule will take the time to speak to his investors, unheard of. Do your own DD, you will see ScripsAmerica is for real. SCRC in 2014 will be a great success.
In recent weeks new investors realizing the potential of SCRC combined have purchased millions of shares. This is proof that the word is getting out on SCRC and is attracting investors with a lot of clout. Several of the new investors have won big on other stock investments and see the same ingredients for success with SCRC. With five "diversified" revenue streams developed, a winning product in Pediatric RapiMeds, the expansion of RapiMeds technology with other OTC medications, funding secured, and the potential of tapping into China's $32B OTC market, Bob Schniderman SCRC CEO, has set the stage for an incredible 2014. SCRC isn't your typical penny stock hedging it's success on an idea or concept. SCRC is a real company with a real product and a CEO who is working overtime for the best of the company and its shareholders. As with any investment, I encourage any new investor to do their own DD. Once you have done this you will agree with the majority of us on this board that the long term potential for SCRC is huge. SCRC's current price offers an incredible buying opportunity and it won't last much longer. With all that Bob Schneiderman has accomplished these last several months, 10X your investment is not out of reason this time next year.
Well said kaleb. I am a long term SCRC investor and I got excited ready your post. Thanks.
To any new investor in SCRC, the following PRs are just a few that you can read on the ScripsAmerica website. Bob Schneiderman, SCRC CEO, has done an outstanding job building five separate revenue streams to launch SCRC into a huge success in 2014. Funding, read the October 14th PR regarding GEM EMG, an unheard accomplishment for a start up penny stock company. The big news is the expansion of SCRC business into the China market. The SCRC Team travelled to China and we are anticipating hearing news of SCRC tapping into this $32B OTC market. Pediatric Rapimeds is just the beginning. The RapiMed technology is currently being looked at for use in sleep medication, vitamins, and other OTC applications. Projections vary depending on who you talk to, but I can see SCRC hitting the $2 or higher in the next 12 - 16 months. The potential with the China market is huge. Whether you are interested in short term gains or long term profits like a lot of us, SCRC is a stock you do not want to pass up. But, as with any investment, I recommend you do your own DD and make your decision. I originally bought in last March and intend to wait it out for the $2 PPS pay day.
TYSONS CORNER, Va., Oct. 14, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) today announced that it has entered into a financing agreement with GEM Global Yield Fund ("GEM Global"), a member of the Global Emerging Markets Group ("GEM"), to provide funding to the Company of up to $2 million.
TYSONS CORNER, Va., Oct. 23, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) today announced that the Company's acquisition target, PIMD International, launched a new product website www.pimdsupplies.com exclusively to market and sell medical supplies online.
TYSONS CORNER, Va., Oct. 28, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) announced today that the Company's due diligence team will travel to China in November to begin formal RapiMed(R) distribution negotiations in preparation for a product launch into the Chinese OTC market, valued at over $32 billion.
TYSONS CORNER, Va., Nov. 4, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that the Company has received and processed $129,794 in orders during October from its recent pharmaceutical distribution joint venture
TYSONS CORNER, Va., Nov. 11, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that it has agreed to invest in Wholesale Rx "WRx" in exchange for an equity position in the company.
TYSONS CORNER, Va., Nov. 20, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that the Company has satisfied $686,962 in trade payables and outstanding convertible notes in exchange for the issuance of shares of its common stock to Ironridge Consumer Co., a division of institutional investor Ironridge Global IV, Ltd. ("Ironridge") which specializes in direct equity investments in consumer product companies. With $686,962 removed from its balance sheet as a result of this transaction, the financing has paid for ScripsAmerica's cost of goods to supply its RapiMed(R) Children's Pain and Fever Reducer product to retail outlets in China as well as to pay outstanding promissory notes.
I don't know how anyone can argue with your post cwell. We are all looking forward to the same type of performance you spelled out. SCRC in 2014 will be a huge success.
Agree 100% d442125. There is nothing wrong in letting new SCRC investors see that others are investing SERIOUSLY in this company. I don't understand the problem with that. Some folks just seem to get hung up on mundane things. SCRC is going to explode in 2014 - Welcome!
Myself and the five others I brought to SCRC account for 518K shares. Not bad for a small time operator.
Talk about being optimistic. No argument here, I would love to see that happen.
And I look forward to that being a multiple of $5.00. Now that would be really nice.
And I will simply sit on the sidelines with my measly 300K shares and watch the competition.
Bsav, you and your BSAV Team have ignited the SCRC rocket ship which is ready for launch. Thanks for all your efforts to put SCRC on the map. I forward to the day we all get together and celebrate this HUGE SCRC success.
Love your positive SCRC attitude cwell. I couldn't state it any better. I'm with you and will hold on and wait for the $2.50 and higher you referred to. This is going to be a fun ride which will begin in 2014. Thanks for your posts.
I am with you martin, I'm in this for the long haul. I am patient and will wait for a huge pay day in 2014.
Jetta, I share your enthusiasm for SCRC in 2014 and I know several others do as well. SCRC will definitely be a winner.
I have been in the pharma industry for over 35 years and I can tell you November and December are always poor profitability months for all types of pharma companies. Yes, the holidays impact sales. Although product is continually shipped to pharmacies via wholesalers, wholesale orders are usually low and patients tend to spend their money on holiday spending versus buying their RX drugs or even OTC medical products. If my experience holds true, SCRC will have a banner month in January when consume purchases will increase dramatically.
And what Bob reported in this morning's PR is just the beginning. The revenue streams he has developed over the last several months are just now beginning to take hold. This is why all along we (the CORE, the Longs, whatever we are called) have always stated 2014 is the year SCRC. 2013 is almost over and SCRC will begin to shine in 2014!!!
Nice buy wilton, you are going to have a huge pay day in 2014.
Its nice to read your posts kansai. You always stay focused on 2014, the year of SCRC. You are so right, our time is near and when it arrives this board will light up with excitement.
Tink, I a confident these low teens will soon be a thing of the past. I have been on board since March and have looked forward to 2014 ever since then. 2014 is the year of SCRC. There is too much happening not to see the revenues begin to flow in and drive the PPS upward. SCRC will prove to be the stock we all thought it would be.
cwell, I agree, next Christmas is going to be a great time for all of us. Go SCRC 2014!!!
Two years and counting, that's how long HYII investors have been waiting for news. There hasn't been any and... well, what can you say?
IT WILL INDEED BE MONSTEROUS!!! From KABOOM to MONSTEROUS, either way I agree, SCRC will explode in 2014!!!
Enough is enough. It seems every time I click on my SCRC IHub favorite instead of reading posts about SCRC and the future of business I am connected to the Joseph Zampetti Celebrity Roast. I read the financial report and it states Mr Zampetti and others as consultants. That's good enough for me - PERIOD! I am interested in learning more about the future of SCRC, the success of the revenue steams Mr. Schneiderman has developed, and the potential of the China marketplace to the SCRC bottom line. What has this board turned into? Lets stay focused on the business and not on individuals. The only individual we should be focused on is Bob Schneiderman, the CEO of SCRC. What he says and does is more important to the business. And in my eyes he has demonstrated his business savvy in building SCRC to where it is today and also demonstrates a sincere interest in the shareholders. To me that's a winning combination. Since March I have acquired close to 300K shares of SCRC because I believe in the business model, the product, and the man running the this soon to be record breaking company. GO SCRC 2014!!!
Very well stated kaleb. Thanks for the post.